HIGHLIGHTS
- who: Xu Zhang from the China Dalian Medical University, China have published the article: Long-term survival in extensive-stage small-cell lung cancer treated with different immune checkpoint inhibitors in multiple-line therapies: A case report and literature review, in the Journal: (JOURNAL)
- what: First, after aggressive and standardized treatment and close follow-up, long-term benefit is still possible, even in SCLC.
SUMMARY
Even with the advent of immunotherapy in recent years, there has been a modest improvement in the efficiency and survival of SCLC treatment with an objective . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.